FOLFOX/bevacizumab plus /- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

被引：0
|
作者：
Schmoll, H. [1 ]
Garlipp, B. [2 ]
Junghanss, C. [3 ]
Vogel, A. [4 ]
Kaiser, U. [5 ]
Florschuetz, A. [6 ]
Kanzler, S. [7 ]
Hannig, C.
Meinert, F. [1 ]
Cygon, F. [1 ]
Stein, A. [8 ]
机构：
[1] Martin Luther Univ Halle Wittenberg, Halle, Germany
[2] Uniklin Magdeburg, Magdeburg, Germany
[3] Univ Rostock, Rostock, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Bernward Krankenhaus, Hildesheim, Germany
[6] Stadtisches Klinikum Dessau, Dessau, Germany
[7] Leopoldina Krankenhaus Schweinfurt, Med Klin 2, Schweinfurt, Germany
[8] Univ Med Ctr Hamburg, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 023
引用
收藏
页数：1
相关论文
共 50 条
  • [21] UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer
    Price, T
    Hill, M
    ONCOLOGY-NEW YORK, 2000, 14 (10): : 28 - 31
  • [22] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    M. Degirmenci
    B. Karaca
    G. Gorumlu
    R. Durusoy
    G. Demir Piskin
    M. T. Bozkurt
    Y. Cirak
    D. Tunali
    B. Karabulut
    U. A. Sanli
    R. Uslu
    Medical Oncology, 2010, 27 : 585 - 591
  • [23] Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer
    Heinemann, Volker
    Hoff, Paulo M.
    ONCOLOGY, 2010, 79 (1-2) : 118 - 128
  • [24] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Hori, Natsuko
    Iwasa, Satoru
    Hashimoto, Hironobu
    Yanai, Takako
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Murakoshi, Kouji
    Yokote, Nobuaki
    Yamamoto, Hiroshi
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 435 - 438
  • [25] Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
    Degirmenci, M.
    Karaca, B.
    Gorumlu, G.
    Durusoy, R.
    Piskin, G. Demir
    Bozkurt, M. T.
    Cirak, Y.
    Tunali, D.
    Karabulut, B.
    Sanli, U. A.
    Uslu, R.
    MEDICAL ONCOLOGY, 2010, 27 (03) : 585 - 591
  • [26] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Natsuko Hori
    Satoru Iwasa
    Hironobu Hashimoto
    Takako Yanai
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Kouji Murakoshi
    Nobuaki Yokote
    Hiroshi Yamamoto
    Yasuhiro Shimada
    International Journal of Clinical Oncology, 2013, 18 : 435 - 438
  • [27] Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
    Suenaga, Mitsukuni
    Fujimoto, Yoshiya
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Akiyoshi, Takashi
    Nagayama, Satoshi
    Fukunaga, Yosuke
    Oya, Masatoshi
    Ueno, Masashi
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    ONCOTARGETS AND THERAPY, 2015, 8 : 1111 - 1118
  • [28] Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Sobrero, A. F.
    Bennicelli, E.
    Pessino, A.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study
    Kwon, Hyuk-Chan
    Oh, Sung Yong
    Lee, Suee
    Kim, Sung-Hyun
    Kim, Hyo-Jin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (46) : 6231 - 6235
  • [30] Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study
    Hyuk-Chan Kwon
    Sung Yong Oh
    Suee Lee
    Sung-Hyun Kim
    Hyo-Jin Kim
    World Journal of Gastroenterology, 2007, (46) : 6231 - 6235
12345